Dr. Scott Tagawa, MD
Claim this profileWeill Cornell Medical College
Area of expertise
Prostate Cancer
Scott Tagawa, MD has run 13 trials for Prostate Cancer. Some of their research focus areas include:
Renal Cell Carcinoma
Scott Tagawa, MD has run 1 trial for Renal Cell Carcinoma. Some of their research focus areas include:
Affiliated Hospitals
Weill Cornell Medical College
NYP/Weill Cornell Medical Center
Clinical Trials Scott Tagawa, MD is currently running
Registry
for Advanced Prostate Cancer
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingdom (UK), and the United States (US). Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices. Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of five years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs. PROMs questionnaires will be collected at enrollment and every three months thereafter. Physician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and/or one year follow-up, at each subsequent change of treatment, and discontinuation of treatment. As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0/M1 CRPC. By collecting blood at enrollment, time of first change in treatment and/or one year follow-up (plasma, cell free DNA, buffy coat / RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment due to progression of disease. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository to identify biomarkers of treatment response and resistance.
Recruiting
1 award
N/A
5 criteria
Pembrolizumab + AR Inhibitors
for Prostate Cancer
This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that increases the immune system's ability to destroy cancer cells). This study will assess whether 225Ac-J591 + pembrolizumab + androgen receptor inhibitor (ARI) is more effective against prostate cancer than pembrolizumab + ARI alone.
Recruiting
2 awards
Phase 1 & 2
9 criteria
More about Scott Tagawa, MD
Clinical Trial Related
4 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Scott Tagawa, MD has experience with
- 225Ac-J591
- Pembrolizumab
- Abiraterone Acetate
- Apalutamide
- Prednisone
- ARX517
Breakdown of trials Scott Tagawa, MD has run
Prostate Cancer
Renal Cell Carcinoma
Kidney Cancer
Prostate Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Scott Tagawa, MD specialize in?
Scott Tagawa, MD focuses on Prostate Cancer and Renal Cell Carcinoma. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Scott Tagawa, MD currently recruiting for clinical trials?
Yes, Scott Tagawa, MD is currently recruiting for 4 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Scott Tagawa, MD has studied deeply?
Yes, Scott Tagawa, MD has studied treatments such as 225Ac-J591, Pembrolizumab, Abiraterone Acetate.
What is the best way to schedule an appointment with Scott Tagawa, MD?
Apply for one of the trials that Scott Tagawa, MD is conducting.
What is the office address of Scott Tagawa, MD?
The office of Scott Tagawa, MD is located at: Weill Cornell Medical College, New York, New York 10065 United States. This is the address for their practice at the Weill Cornell Medical College.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.